Dementia Clinical Trial
— DIAN-TUOfficial title:
A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled, Two-part Adaptive Design, Platform Trial of Investigational Treatments for Primary Prevention of Disease Progression in Dominantly Inherited Alzheimer's Disease
Verified date | June 2024 |
Source | Washington University School of Medicine |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose is to evaluate the biomarker effect, safety, and tolerability of investigational study drugs in participants who are known to have an Alzheimer's disease (AD)-causing mutation. Part 1 will determine if treatment with the study drug prevents or slows the rate of amyloid beta (Aβ) pathological disease accumulation demonstrated by Aβ positron emission tomography (PET) imaging. Part 2 will evaluate the effect of early Aβ plaque reduction/prevention on disease progression by assessing downstream non-Aβ biomarkers of AD (e.g., CSF total tau, p-tau, NfL) compared to an external control group from the DIAN-OBS natural history study and the DIAN-TU-001 placebo-treated participants.
Status | Suspended |
Enrollment | 220 |
Est. completion date | March 2034 |
Est. primary completion date | November 2029 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Informed consent form (ICF) is signed and dated by the participant and study partner, or by the participant's legally acceptable representative (LAR) if applicable, according to local regulations for the ICF and, if applicable, the DIAN-TU cognitive run-in (CRI) ICF and/or country-specific ICFs. 2. Participant is at least 18 years old. 3. Women of childbearing potential, if partner is not sterilized, must agree to use effective contraceptive measures (e.g., hormonal contraception, intra-uterine device, sexual abstinence, barrier method with spermicide) from Screening visit (V1) until 16 weeks after last dose of study drug. 4. Participants must fulfill mutation status and EYO criteria: 1. Participant is a carrier of a mutation in an APP, PSEN1, or PSEN2 gene that is associated with DIAD or does not know their mutation status and has a 50% chance of having an AD-causing mutation (e.g., parent or biological sibling clinically affected with known AD-causing mutation in family). 2. Participant is -25 to -11 EYO based on their mutation type or family pedigree (refer to Global Manual of Operations for calculation of EYO). Note: If the at-risk parent is deemed a non-carrier through confirmed genetic testing at any time during the study, the participant will be withdrawn. 5. Cognitive status of participant is normal (CDR 0). 6. Participant's confirmed primary language is a DIAN-TU study-approved language. 7. Participant has adequate visual and auditory abilities to perform all aspects of the cognitive and clinical assessments. 8. If participant is receiving stable doses of medication(s) for the treatment of non-excluded medical condition(s) for at least 30 days prior to CRI Entry visit and Screening visit (V1) except for medications taken for episodic conditions (e.g., migraine abortive therapy, antibiotics, and other medications for upper respiratory and gastrointestinal ailments). 9. The participant has a study partner who in the PI's judgment can provide accurate information as to the participant's cognitive and functional abilities, who agrees to provide information at the study visits that require study partner input for scale completion, and who signs the necessary ICF, if applicable. 10. The participant agrees not to donate blood or blood products for transfusion from the time of Screening (V1) for a study drug arm, for the duration of the study, and for 1 year after the final dose of study drug. Donation of blood or blood products for transfusion is allowed during the CRI period. 11. In the opinion of the PI, the participant will be compliant and have a high probability of completing the study. 12. The participant is able and willing to complete all study-related testing, evaluations, and procedures. Exclusion Criteria: 1. Significant neurologic disease (other than AD) or psychiatric disease that may currently or during the study affect cognition or the participant's ability to complete the study. This would include disorders such as: recent or severe head trauma causing cognitive change, seizure disorder, neurodegenerative disease other than DIAD, hydrocephalus, cerebral/spinal hematoma, inflammatory disease, CNS infection (e.g., encephalitis or meningitis), neoplasm, toxic exposure, metabolic disorder (including hypoxic or hypoglycemic episodes) or endocrine disorder; psychiatric disorders such as schizophrenia, schizoaffective disorder, bipolar disorder or major depression, or any other psychiatric condition/disorder which could significantly interfere with the participant's cooperative participation (e.g., prominent anxiety, agitation or behavioral problems). Disorders that are controlled medically or remote history of these disorders (e.g., history of febrile seizures in childhood) that are not likely to interfere with cognitive function and compliance with study procedures are not exclusionary. 2. At high risk for suicide, e.g., significant suicidal ideation or attempt within last 12 months, current major depression (as defined in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition [DSM-V]), or increased suicide risk based on screening Columbia Suicide Severity Rating Scale (C-SSRS). Current stable mild depression or current use of antidepressant medications is not exclusionary. 3. History of clinically evident stroke or history of clinically important carotid or vertebrobasilar stenosis, plaque, or other prominent risk factor for stroke or cerebral hemorrhage (including atrial fibrillation and anticoagulation, documented transient ischemic attack [TIA] in the last 12 months). Low dose aspirin (= 325 mg daily) is not exclusionary. 4. Alcohol or substance use sufficient to meet DSM-V criteria currently or within the past year. 5. History of or Baseline visit brain MRI scan indicative of any other significant abnormality, including but not limited to > 5 definite microhemorrhages, history or evidence of a single prior hemorrhage > 1 cm3, 2 or more subcortical infarcts, evidence of a single prior cortical infarct > 1 cm3, evidence of a cerebral contusion, encephalomalacia, aneurysms, vascular malformations, subdural hematoma, or space-occupying lesions (e.g., arachnoid cysts or brain tumors, such as meningioma), hydrocephalus (other than hydrocephalus ex vacuo). Minor or clinically insignificant imaging findings are not exclusionary. Participants with > 5 definite microhemorrhages or > 1 area of leptomeningeal hemosiderosis will be evaluated on a case-by-case basis by the site PI or designated sub-investigator and the PAL and medical director or designee. 6. Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, or foreign metal objects in the eyes, skin, or body which would preclude MRI scan. 7. Uncontrolled hypertension within 6 months prior to screening (e.g., sustained systolic blood pressure [BP] >160 mm Hg or diastolic blood pressure > 95 mm Hg). 8. Myocardial infarction or other myocardial ischemic events within the last 2 years. 9. Heart failure that results in limitation of physical activity (e.g., New York Heart Association [NYHA] functional classification stage 2 or higher). 10. History of atrial fibrillation unless more than 1 year ago, and no structural lesions (e.g., atrial enlargement or cardiomyopathy) that would increase risk of stroke. 11. 12-lead ECG: Clinically significant abnormalities including Bazett's corrected QT (QTc) interval greater than 450 msec for males and 470 msec for females; in participants above 65 years of age: 470 msec (atrioventricular [AV]-block I° allowed; right bundle branch block [RBBB] allowed). 12. Alanine aminotransferase (ALT) = 2 times the upper limit of normal or aspartate aminotransferase (AST) = 3 times the upper limit of normal or Baseline total bilirubin = 2 times the upper limit of normal. 13. Creatinine clearance lower than 30 mL/min according to Cockcroft-Gault formula (if confirmed at re-test). 14. Clinically significant abnormalities in urinalysis. 15. History of Human Immunodeficiency Virus (HIV) infection, history of Hepatitis B infection within the past year, history of Hepatitis C infection which has not been adequately treated or history of spirochete infection of the CNS, (e.g., syphilis, Lyme or borreliosis). 16. Known allergies, hypersensitivity, or intolerance to study drug or its excipients (see current investigator's brochures [IB]) or sensitivity to study-drug specific PET imaging agents. 17. Treatment with immunosuppressive medications (e.g., systemic corticosteroids) within 90 days prior to the CRI Entry and Baseline (V2) visit (topical and nasal corticosteroids and inhaled corticosteroids for asthma are permitted) or chemotherapeutic agents for malignancy within the last 3 years. 18. Current clinically significant abnormalities of thyroid function, or clinically significant deficiency in vitamin B12. 19. Screening hemoglobin A1c (HbA1c) > 8% (retesting is permitted if slightly elevated) or poorly controlled insulin-dependent diabetes (including hypoglycemic episodes). Participants may be rescreened after 3 months to allow optimization of diabetic control. 20. Morbid obesity with significant comorbidities or that would preclude MRI imaging. 21. Current use of anticoagulants (e.g., warfarin, dabigatran, rivaroxaban, or apixaban). Daily use of low dose (< 325 mg) aspirin is not exclusionary. 22. Have been exposed to a monoclonal antibody targeting Aß peptide within the past 6 months or 5 half-lives from screening, whichever is longer. 23. Received any other investigational pharmacological treatment within 3 months of Screening or 5 half-lives, whichever is longer. 24. Lack of sufficient venous access. 25. Clinically relevant abnormalities in hematology, coagulation, or clinical chemistry. 26. History of cancer within the last 3 years, except basal cell carcinoma, non-squamous skin carcinoma, prostate cancer, or carcinoma in situ with no significant progression over the past 2 years. 27. Any other medical condition that could be expected to progress, recur, or change to such an extent that it could bias the assessment of the clinical or mental status of the participant to a significant degree or put the participant at special risk. 28. Currently, or within the last month prior to screening, participated in a clinical study, including a nonpharmacological study, without prior approval. 29. Positive urine or serum pregnancy test or plans to become pregnant during the study. 30. Currently breastfeeding. Participants must agree to refrain from breastfeeding from the time of signed ICF until 16 weeks after the last dose of study drug. 31. Participants with the "Dutch" APP E693Q mutation. 32. Unable to fully complete CRI Entry visit and baseline visit (V2) procedures with appropriate cognitive and clinical scores for eligibility (e.g., mild dementia). |
Country | Name | City | State |
---|---|---|---|
Argentina | Instituto de Investigaciones Neurologicas Raul Carrea, FLENI | Ciudad Autonoma de Buenos Aire | |
Australia | Mental Health Research Institute | Melbourne | Victoria |
Australia | Neuroscience Research Australia | Randwick | New South Wales |
Canada | CHU de Quebec - Hôpital de l' Enfant Jésus | Québec | |
Canada | Sunnybrook Health Sciences Centre | Toronto | Ontario |
Canada | UBC Hospital | Vancouver | British Columbia |
Canada | McGill Center for Studies in Aging | Verdun | Quebec |
Colombia | Grupo de Neurociencias Sede de la Universidad de Antioquia | Medellín | |
France | Hopital Neurologique Pierre Wertheimer | Bron cedex | Rhone |
France | Hopital Roger Salengro - CHU Lille | Lille | Nord |
France | Groupe Hospitalier Pitie-Salpetriere | Paris cedex 13 | Paris |
France | CHU de Rouen - Hôpital Charles Nicolle | Rouen | Seine Maritime |
France | CHU de Toulouse - Hôpital Purpan | Toulouse | Haute Garonne |
Germany | LMU-Campus Grosshadern | Muenchen | Bayern |
Germany | Universitaetsklinikum Tubingen | Tübingen | Baden Wuerttemberg |
Ireland | St Vincent's University Hospital | Dublin | |
Italy | IRCCS Centro San Giovanni di Dio Fatebenefratelli | Brescia | |
Italy | Azienda Ospedaliera Universitaria Careggi | Firenze | |
Mexico | Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez | Mexico | Distrito Federal |
Netherlands | Brain Research Center | Amsterdam | |
Puerto Rico | University of Puerto Rico, School of Medicine | San Juan | |
Spain | Hospital Clínic I Provincial de Barcelona | Barcelona | |
United Kingdom | The National Hospital for Neurology and Neurosurgery | London | Greater London |
United States | Emory University | Atlanta | Georgia |
United States | University of Alabama in Birmingham | Birmingham | Alabama |
United States | Kerwin Research and Memory Center | Dallas | Texas |
United States | Indiana University School of Medicine | Indianapolis | Indiana |
United States | University of California San Diego Medical Center | La Jolla | California |
United States | USC Keck School of Medicine | Los Angeles | California |
United States | Yale University School of Medicine | New Haven | Connecticut |
United States | Advocate Lutheran General Hospital | Park Ridge | Illinois |
United States | University of Pittsburgh | Pittsburgh | Pennsylvania |
United States | Butler Hospital | Providence | Rhode Island |
United States | Washington University in St. Louis | Saint Louis | Missouri |
United States | University of Washington | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
Washington University School of Medicine | Alzheimer's Association, Genentech, Inc., Hoffmann-La Roche, National Institute on Aging (NIA) |
United States, Argentina, Australia, Canada, Colombia, France, Germany, Ireland, Italy, Mexico, Netherlands, Puerto Rico, Spain, United Kingdom,
Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC; Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012 Aug 30;367(9):795-804. doi: 10.1056/NEJMoa1202753. Epub 2012 Jul 11. Erratum In: N Engl J Med. 2012 Aug 23;367(8):780. — View Citation
Grill JD, Bateman RJ, Buckles V, Oliver A, Morris JC, Masters CL, Klunk WE, Ringman JM; Dominantly Inherited Alzheimer's Network. A survey of attitudes toward clinical trials and genetic disclosure in autosomal dominant Alzheimer's disease. Alzheimers Res Ther. 2015 Jul 22;7(1):50. doi: 10.1186/s13195-015-0135-0. eCollection 2015. — View Citation
McDade E, Bateman RJ. Stop Alzheimer's before it starts. Nature. 2017 Jul 12;547(7662):153-155. doi: 10.1038/547153a. No abstract available. — View Citation
McDade E, Wang G, Gordon BA, Hassenstab J, Benzinger TLS, Buckles V, Fagan AM, Holtzman DM, Cairns NJ, Goate AM, Marcus DS, Morris JC, Paumier K, Xiong C, Allegri R, Berman SB, Klunk W, Noble J, Ringman J, Ghetti B, Farlow M, Sperling RA, Chhatwal J, Salloway S, Graff-Radford NR, Schofield PR, Masters C, Rossor MN, Fox NC, Levin J, Jucker M, Bateman RJ; Dominantly Inherited Alzheimer Network. Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology. 2018 Oct 2;91(14):e1295-e1306. doi: 10.1212/WNL.0000000000006277. Epub 2018 Sep 14. — View Citation
Mills SM, Mallmann J, Santacruz AM, Fuqua A, Carril M, Aisen PS, Althage MC, Belyew S, Benzinger TL, Brooks WS, Buckles VD, Cairns NJ, Clifford D, Danek A, Fagan AM, Farlow M, Fox N, Ghetti B, Goate AM, Heinrichs D, Hornbeck R, Jack C, Jucker M, Klunk WE, Marcus DS, Martins RN, Masters CM, Mayeux R, McDade E, Morris JC, Oliver A, Ringman JM, Rossor MN, Salloway S, Schofield PR, Snider J, Snyder P, Sperling RA, Stewart C, Thomas RG, Xiong C, Bateman RJ. Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. Rev Neurol (Paris). 2013 Oct;169(10):737-43. doi: 10.1016/j.neurol.2013.07.017. Epub 2013 Sep 6. — View Citation
Ryman DC, Acosta-Baena N, Aisen PS, Bird T, Danek A, Fox NC, Goate A, Frommelt P, Ghetti B, Langbaum JB, Lopera F, Martins R, Masters CL, Mayeux RP, McDade E, Moreno S, Reiman EM, Ringman JM, Salloway S, Schofield PR, Sperling R, Tariot PN, Xiong C, Morris JC, Bateman RJ; Dominantly Inherited Alzheimer Network. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology. 2014 Jul 15;83(3):253-60. doi: 10.1212/WNL.0000000000000596. Epub 2014 Jun 13. — View Citation
Wang G, Berry S, Xiong C, Hassenstab J, Quintana M, McDade EM, Delmar P, Vestrucci M, Sethuraman G, Bateman RJ; Dominantly Inherited Alzheimer Network Trials Unit. A novel cognitive disease progression model for clinical trials in autosomal-dominant Alzheimer's disease. Stat Med. 2018 Sep 20;37(21):3047-3055. doi: 10.1002/sim.7811. Epub 2018 May 14. — View Citation
Weng H, Bateman R, Morris JC, Xiong C. Validity and power of minimization algorithm in longitudinal analysis of clinical trials. Biostat Epidemiol. 2017;1(1):59-77. doi: 10.1080/24709360.2017.1331822. Epub 2017 Jun 13. — View Citation
Weninger S, Carrillo MC, Dunn B, Aisen PS, Bateman RJ, Kotz JD, Langbaum JB, Mills SL, Reiman EM, Sperling R, Santacruz AM, Tariot PN, Welsh-Bohmer KA. Collaboration for Alzheimer's Prevention: Principles to guide data and sample sharing in preclinical Alzheimer's disease trials. Alzheimers Dement. 2016 May;12(5):631-2. doi: 10.1016/j.jalz.2016.04.001. No abstract available. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Part 1: Difference in change from baseline in amyloid deposition as measured by [11C]PiB-PET average cortical composite between active drug and placebo groups. | Comparison of the study drug to placebo on change from baseline to week 208 in amyloid deposition as measured by [11C]PiB-PET cortical composite SUVR, which is derived from the average of cortical regions of interest (superior frontal, rostral middle frontal, superior temporal, middle temporal, lateral orbito-frontal, medial orbito-frontal and precuneus). | Baseline and Week 208 | |
Primary | Part 2: Odds ratio between treated group and the external control group of being in the lower biomarker disease progression stage based on two-stage modeling of 6 biomarkers. | The primary endpoint will be the odds ratio of being in the lower biomarker disease progression stage after treatment with study drug compared to the external control group (DIAN-OBS and DIAN-TU-001 placebo. Disease progression will be based on two-stage modeling of 6 biomarkers (CSF pT153/T153 ratio, CSF pT205/T205 ratio, CSF MTBR-tau299, MRI hippocampal volume, CSF NfL, and MRI precuneus thickness). These biomarkers represent tau and neurodegenerative pathobiological events in the disease cascade for temporally different periods of the pre-symptomatic phases of the disease. | Part 2 Week 208 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05686486 -
Gentle Gymnastics and Relationship Between Family Caregivers and Residents With Dementia in Nursing Homes
|
N/A | |
Terminated |
NCT05451693 -
Outreach-ER: A Dementia Care Intervention Program
|
||
Recruiting |
NCT05820919 -
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
|
N/A | |
Enrolling by invitation |
NCT06040294 -
Dementia and Disability Simulation for College Nursing Students' Senior Activity Facilitation Skills
|
N/A | |
Completed |
NCT05114187 -
An Internet-Based Education Program for Care Partners of People Living With Dementia
|
N/A | |
Recruiting |
NCT06322121 -
Vascular Aspects in Dementia: Part 2
|
||
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Completed |
NCT04426838 -
Cognitive Behavioral Therapy for Insomnia for the Dementia Caregiving Dyad
|
N/A | |
Recruiting |
NCT03462485 -
Pilot Study of the Effects of Playing Golf on People With Dementia
|
N/A | |
Active, not recruiting |
NCT03677284 -
Managing Time With Dementia: Effects of Time Assistive Products in People With Dementia
|
N/A | |
Completed |
NCT03849937 -
Changing Talk Online (CHATO) Study
|
N/A | |
Recruiting |
NCT06284213 -
Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia Consortium
|
||
Recruiting |
NCT05579236 -
Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease
|
||
Completed |
NCT05080777 -
Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care Systems
|
N/A | |
Completed |
NCT04571697 -
A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy
|
||
Completed |
NCT03583879 -
Using Gait Robotics to Improve Symptoms of Parkinson's Disease
|
N/A | |
Recruiting |
NCT06033066 -
Financial Incentives and Recruitment to the APT Webstudy
|
N/A | |
Active, not recruiting |
NCT05204940 -
Longitudinal Observational Biomarker Study
|
||
Recruiting |
NCT05684783 -
Dementia Champions in Homecare
|
||
Completed |
NCT03147222 -
Function Focused Care: Fracture Care at Home
|
N/A |